Oncology, diabetes drive Indian pharma; Mounjaro sales up 880% to ₹1,228 Cr

For biotech and pharma executives, the July 2026 Indian market data is a case study in value creation over volume. The 12.1% top-line growth was powered not by increased prescriptions but by a 5.9% price hike and a 3.8% contribution from new, often patented products. This pivot toward premiumization — epitomized by Mounjaro’s ₹1,228 crore sales — signals that India’s vast disease burden is increasingly addressable with innovative biologics and specialty drugs, reshaping market access and portfolio priorities for domestic and multinational players alike.

The Indian pharmaceutical market (IPM) posted a robust 12.1% year-on-year value growth in July 2026, accelerating sharply from 7.3% in the previous period, according to PharmaTrac's monthly report. This headline expansion, however, masks a deeply bifurcated recovery: unit growth crawled at just 1.6%, while pricing and new product introductions drove the bulk of the advance. PharmaTrac’s decomposition of the 12.1% growth reveals 5.9 percentage points from price increases, 3.8 from new products, and only 2.4 from volume, underscoring a fundamental shift toward higher-value therapies, premium brands, and inflationary pricing rather than broad-based prescription expansion. On a moving annual total basis, the IPM grew 10.2% in value against a meager 1.1% unit growth, confirming that the divergence is not a one-month blip but a structural trend.

“

The 12.1% top-line growth was powered not by increased prescriptions but by a 5.9% price hike and a 3.8% contribution from new, often patented products.

The therapy-area data highlights where the value is being created. The cardiac segment remained the largest by sales at Rs 3,299 crore, growing a healthy 14.7%, reflecting India’s rising burden of cardiovascular disease and the uptake of newer, costlier medications. Anti-diabetic therapies surged 17.6% to Rs 2,237 crore, propelled by the explosive adoption of GLP-1 receptor agonists, as evidenced by Eli Lilly's Mounjaro (tirzepatide), which alone recorded Rs 1,228 crore in sales — an astronomical 880% jump that added Rs 1,103 crore year-on-year. This single brand now accounts for more than half of the entire anti-diabetic segment, a concentration that signals a profound therapeutic shift and enormous market potential for innovative biologics and peptides. Oncology (anti-neoplastics) grew 21.1%, the fastest among major categories, driven by new immunotherapies and targeted agents entering the Indian market. Vaccines also grew 17.5%, reflecting continued public and private immunization drive momentum post-pandemic. Other segments such as respiratory (11.2%), pain/analgesics (11.4%), neuro/CNS (13.4%), gastrointestinal (Rs 2,820 crore), and anti-infectives (Rs 2,470 crore) posted double-digit value growth, though their unit growth likely remained anemic.

For the biotech and pharma industry, this data presents a strategic pivot. India’s pharma market, historically dominated by low-cost generics and volume-led growth, is maturing into a value-driven marketplace where patented, complex, and specialty therapies command disproportionate share gains. The near-tripling of price contribution (from roughly 3–4% in earlier years, based on PharmaTrac’s trend data) suggests manufacturers are increasingly willing to take price increases, partly due to rising input costs and partly because the market is willing to absorb them for differentiated products. New product launches — particularly in metabolic, oncologic, and CNS disorders — are not just incremental; they are reshaping category hierarchies, as Mounjaro’s stellar performance demonstrates.